INBX
Inhibrx Biosciences, Inc.
NASDAQ: INBX · HEALTHCARE · BIOTECHNOLOGY
$129.21
+3.52% today
Updated 2026-04-30
Market cap
$1.82B
P/E ratio
—
P/S ratio
1,402.52x
EPS (TTM)
$-9.04
Dividend yield
—
52W range
$11 – $155
Volume
0.3M
Inhibrx Biosciences, Inc. (INBX) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-18.11M | $-18.75M | $-23.09M | $-32.08M | $-47.97M | $-80.32M | $-115.30M | $-193.31M | $-194.41M | $-129.79M |
| Capital expenditures | $215000.00 | $1.34M | $1.43M | $1.81M | $1.36M | $864000.00 | $686000.00 | $4.59M | $2.60M | $31000.00 |
| Depreciation | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $552000.00 | $1.18M | $2.48M | $3.97M | $5.02M | $15.05M | $20.45M | $24.85M | $58.52M | $11.14M |
| Free cash flow | $-18.32M | $-20.09M | $-24.52M | $-33.89M | $-49.33M | $-81.19M | $-115.99M | $-197.90M | $-197.01M | $-129.82M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | $1.38M | $828000.00 | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — | — | — | — |